181 related articles for article (PubMed ID: 36544775)
1. A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice.
Ma Q; Hu X; Liu F; Cao Z; Han L; Zhou K; Bai Y; Zhang Y; Nan Y; Lv Q; Rao J; Wu T; Yang X; He H; Ju D; Xu H
Front Immunol; 2022; 13():1011442. PubMed ID: 36544775
[TBL] [Abstract][Full Text] [Related]
2. The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy.
Ma Y; Chen Y; Xu H; Du N
Front Immunol; 2023; 14():1228399. PubMed ID: 37638046
[TBL] [Abstract][Full Text] [Related]
3. A bifunctional fusion protein protected against diabetic nephropathy by suppressing NLRP3 activation.
Shen Y; Xu Y; Shen P; Shen P; Bian Q; Han L; Cao Z; Fan J; Zeng X; Zhang Y; Guo Z; Ju D; Mei X
Appl Microbiol Biotechnol; 2023 Apr; 107(7-8):2561-2576. PubMed ID: 36843198
[TBL] [Abstract][Full Text] [Related]
4. VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses.
Shen Y; Chen W; Han L; Bian Q; Fan J; Cao Z; Jin X; Ding T; Xian Z; Guo Z; Zhang W; Ju D; Mei X
Acta Pharm Sin B; 2021 Jan; 11(1):127-142. PubMed ID: 33532185
[TBL] [Abstract][Full Text] [Related]
5. Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice.
Ma Y; Xie D; Liu J; Han X; Xu H; Chen Y
Int Immunopharmacol; 2023 Feb; 115():109715. PubMed ID: 37724955
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation.
Wang S; Li Y; Fan J; Zhang X; Luan J; Bian Q; Ding T; Wang Y; Wang Z; Song P; Cui D; Mei X; Ju D
Cell Death Dis; 2017 Jul; 8(7):e2937. PubMed ID: 28726774
[TBL] [Abstract][Full Text] [Related]
7. Anti-proteinuria effect of antibody against ANGPTL3 coil-coiled domain on adriamycin-induced nephropathy in mice.
Han X; Dai R; Zhai Y; Shen Q; Sun L; Liu H; Xu H
Biochem Biophys Res Commun; 2019 Aug; 516(3):812-818. PubMed ID: 31256934
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
9. Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage.
Lv Q; Han X; Ni J; Ma Q; Dai R; Liu J; Liu J; Zhai Y; Shen Q; Sun L; Liu H; Rao J; Xu H
Cell Death Dis; 2022 Oct; 13(10):867. PubMed ID: 36229446
[TBL] [Abstract][Full Text] [Related]
10. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model.
Gao Y; Ma Y; Xie D; Jiang H
Int Immunopharmacol; 2022 Jun; 107():108711. PubMed ID: 35338958
[TBL] [Abstract][Full Text] [Related]
11. Minnelide combined with Angptl3 knockout completely protects mice with adriamycin nephropathy via suppression of TGF-β1-Smad2 and p53 pathways.
Ji B; Liu J; Ma Y; Yin Y; Xu H; Shen Q; Yu J
Int Immunopharmacol; 2023 Feb; 115():109656. PubMed ID: 36608441
[TBL] [Abstract][Full Text] [Related]
12. Huangkui capsule alleviates renal tubular epithelial-mesenchymal transition in diabetic nephropathy via inhibiting NLRP3 inflammasome activation and TLR4/NF-κB signaling.
Han W; Ma Q; Liu Y; Wu W; Tu Y; Huang L; Long Y; Wang W; Yee H; Wan Z; Tang R; Tang H; Wan Y
Phytomedicine; 2019 Apr; 57():203-214. PubMed ID: 30785016
[TBL] [Abstract][Full Text] [Related]
13. Podocyte protection by Angptl3 knockout via inhibiting ROS/GRP78 pathway in LPS-induced acute kidney injury.
Ma Y; Liu J; Liu H; Han X; Sun L; Xu H
Int Immunopharmacol; 2022 Apr; 105():108549. PubMed ID: 35086056
[TBL] [Abstract][Full Text] [Related]
14. Spop ameliorates diabetic nephropathy through restraining NLRP3 inflammasome.
Wang B; Dai Z; Gao Q; Liu Y; Gu G; Zheng H
Biochem Biophys Res Commun; 2022 Feb; 594():131-138. PubMed ID: 35081502
[TBL] [Abstract][Full Text] [Related]
15. Notoginsenoside R1 ameliorates podocyte injury in rats with diabetic nephropathy by activating the PI3K/Akt signaling pathway.
Huang G; Lv J; Li T; Huai G; Li X; Xiang S; Wang L; Qin Z; Pang J; Zou B; Wang Y
Int J Mol Med; 2016 Oct; 38(4):1179-89. PubMed ID: 27571993
[TBL] [Abstract][Full Text] [Related]
16. Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine adriamycin-induced nephropathy by attenuating podocyte loss.
Dai R; Liu H; Han X; Liu J; Zhai Y; Rao J; Shen Q; Xu H
BMC Nephrol; 2019 May; 20(1):185. PubMed ID: 31126248
[TBL] [Abstract][Full Text] [Related]
17. Pyrroloquinoline quinone ameliorates renal fibrosis in diabetic nephropathy by inhibiting the pyroptosis pathway in C57BL/6 mice and human kidney 2 cells.
Qu X; Zhai B; Liu Y; Chen Y; Xie Z; Wang Q; Wu Y; Liu Z; Chen J; Mei S; Wu J; You Z; Yu Y; Wang Y
Biomed Pharmacother; 2022 Jun; 150():112998. PubMed ID: 35489281
[TBL] [Abstract][Full Text] [Related]
18. FOXM1-activated SIRT4 inhibits NF-κB signaling and NLRP3 inflammasome to alleviate kidney injury and podocyte pyroptosis in diabetic nephropathy.
Xu X; Zhang L; Hua F; Zhang C; Zhang C; Mi X; Qin N; Wang J; Zhu A; Qin Z; Zhou F
Exp Cell Res; 2021 Nov; 408(2):112863. PubMed ID: 34626587
[TBL] [Abstract][Full Text] [Related]
19. A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation.
Zhang C; Zhu X; Li L; Ma T; Shi M; Yang Y; Fan Q
Diabetes Metab Syndr Obes; 2019; 12():1297-1309. PubMed ID: 31447572
[TBL] [Abstract][Full Text] [Related]
20. Elevated angiopoietin-like protein 3 serum levels in diabetic nephropathy patients and its association with renal function and lipid profile.
Azadi SM; Fadaei R; Omid-Shafaat R; Hosseini J; Moradi N
BMC Nephrol; 2023 Jun; 24(1):172. PubMed ID: 37312105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
